Insider Buying: Sarepta Therapeutics Inc (NASDAQ:SRPT) Director Acquires $159,250.00 in Stock

Share on StockTwits

Sarepta Therapeutics Inc (NASDAQ:SRPT) Director Richard Barry acquired 1,300 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average price of $122.50 per share, with a total value of $159,250.00. Following the acquisition, the director now directly owns 3,173,365 shares of the company’s stock, valued at approximately $388,737,212.50. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Richard Barry also recently made the following trade(s):

  • On Wednesday, August 14th, Richard Barry purchased 3,700 shares of Sarepta Therapeutics stock. The shares were purchased at an average price of $122.50 per share, with a total value of $453,250.00.

Shares of Sarepta Therapeutics stock opened at $121.97 on Friday. The company has a fifty day simple moving average of $145.64 and a 200-day simple moving average of $131.14. Sarepta Therapeutics Inc has a 12-month low of $95.21 and a 12-month high of $165.87. The company has a current ratio of 12.17, a quick ratio of 11.15 and a debt-to-equity ratio of 0.35. The stock has a market cap of $9.23 billion, a price-to-earnings ratio of -22.34 and a beta of 2.01.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.08) by ($2.66). Sarepta Therapeutics had a negative net margin of 165.52% and a negative return on equity of 56.64%. The company had revenue of $94.67 million during the quarter, compared to analyst estimates of $91.05 million. During the same quarter in the previous year, the company posted ($1.67) EPS. The company’s quarterly revenue was up 28.8% on a year-over-year basis. On average, analysts forecast that Sarepta Therapeutics Inc will post -4.89 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Sarepta Therapeutics by 3.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,232,424 shares of the biotechnology company’s stock valued at $947,017,000 after buying an additional 232,752 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Sarepta Therapeutics by 10.1% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,902,227 shares of the biotechnology company’s stock valued at $592,943,000 after purchasing an additional 359,160 shares during the last quarter. Janus Henderson Group PLC raised its position in Sarepta Therapeutics by 2.3% in the 2nd quarter. Janus Henderson Group PLC now owns 2,728,082 shares of the biotechnology company’s stock valued at $414,532,000 after purchasing an additional 62,039 shares during the last quarter. TimesSquare Capital Management LLC raised its position in Sarepta Therapeutics by 14.5% in the 2nd quarter. TimesSquare Capital Management LLC now owns 1,255,160 shares of the biotechnology company’s stock valued at $190,722,000 after purchasing an additional 159,225 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC raised its position in Sarepta Therapeutics by 1.7% in the 1st quarter. Gilder Gagnon Howe & Co. LLC now owns 992,371 shares of the biotechnology company’s stock valued at $118,281,000 after purchasing an additional 16,666 shares during the last quarter. Institutional investors and hedge funds own 95.57% of the company’s stock.

SRPT has been the subject of several analyst reports. Evercore ISI reiterated a “buy” rating and set a $200.00 price target on shares of Sarepta Therapeutics in a report on Thursday, August 8th. BidaskClub cut shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. HC Wainwright set a $267.00 price target on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Monday, June 17th. ValuEngine cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Finally, Royal Bank of Canada boosted their price target on shares of Sarepta Therapeutics from $188.00 to $220.00 and gave the stock an “outperform” rating in a report on Monday, July 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and twenty have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $208.29.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

See Also: Do investors pay a separate front-end load every time they buy additional shares?

Insider Buying and Selling by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Meridian Bioscience  Cut to Sell at ValuEngine
Meridian Bioscience Cut to Sell at ValuEngine
Trevena  Raised to “Buy” at Zacks Investment Research
Trevena Raised to “Buy” at Zacks Investment Research
2U  Now Covered by Analysts at William Blair
2U Now Covered by Analysts at William Blair
Aegis Reaffirms Buy Rating for Yield10 Bioscience
Aegis Reaffirms Buy Rating for Yield10 Bioscience
SunOpta, Inc.  Director Acquires $156,748.80 in Stock
SunOpta, Inc. Director Acquires $156,748.80 in Stock
First Majestic Silver Corp.  Senior Officer Sells C$179,375.00 in Stock
First Majestic Silver Corp. Senior Officer Sells C$179,375.00 in Stock


© 2006-2019 Ticker Report